

Report Information

More information from: <https://www.marketresearchfuture.com/reports/uveitis-treatment-market-8457>

Uveitis Treatment Market Research Report- Forecast till 2027

Report / Search Code: MRFR/HC/6985-HCR

Publish Date: November, 2023

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 3250.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

Description:

Uveitis Treatment Market Overview

The Uveitis Treatment Market is expected to reach USD 1.03 Billion by 2032 at CAGR 5.6% during the forecast period 2023-2032. Uveitis is a form of inflammation that occurs in the middle layer of the eyeball known as the uvea. It is accompanied by symptoms such as pain, redness of the eyes, and blurred vision. It mainly occurs in people aged between 20 to 50 years. There are three main types of uveitis anterior uveitis, posterior uveitis, and intermediate uveitis.

For instance, in June 2016, AbbVie Inc received FDA (Food and Drug Administration) approvals for its HUMIRA in the treatment of non-infectious intermediate, posterior, and panuveitis. This helped it to strengthen its uveitis treatment product portfolio.

A key factor propelling the uveitis treatment market is the worldwide increase in uveitis incidence and prevalence. The increased incidence of uveitis can be attributed to a number of factors, including autoimmune illnesses, infections, and inflammatory disorders. Moreover, the therapy of uveitis has also been progressed thanks to the discovery of new drugs such biologic treatments, immunosuppressants, and targeted medicines.

The development of more precise and efficient methods of treatment is a major factor driving the market forward. Therefore, the early diagnosis and quick treatment of uveitis have resulted from rising awareness about the condition among healthcare professionals and patients. As a result, there is a greater need for effective treatments for uveitis.

Rapid market expansion may be attributed, in part, to the increase in spending on research projects in the ophthalmology sector. Refractory posterior or intermediate uveitis are the subject of a growing number of clinical trials across the world. Several randomized, controlled trials of alternative treatments to the conventional corticosteroid therapy for noninfectious uveitis, such as mycophenolate mofetil and methotrexate, are currently enrolling patients.

Moreover, the improvement of therapy choices for ocular inflammatory problems is largely attributable to the creation of biological therapies through intensive R&D efforts. As a result, this is increasing the need for these medications and stimulating the market.

May 2023:The Israeli firm BioNanoSim will partner with the Greek manufacturer RAFARM to launch BNS Ophthalmics (BNSO), which will sell pharmaceuticals designed by BNS to treat critical eye illnesses. The company's flagship product, BNSO-1, is a topically applied anti-inflammatory drug. Chronic Anterior Uveitis is an inflammation of the iris that can be caused by a number of infectious and noninfectious disorders. By the end of the year, BNSO plans to begin a clinical research employing the innovative medication in patients with this condition.

Market Influencer

Rising prevalence of uveitis, increasing R&D expenditure, and product launches are likely to impact the growth of the uveitis treatment market positively.

Market Drivers

- Increased R&D expenditure in the healthcare industry will support the growth of the uveitis treatment market.
- The growth of the market is driven by the increasing number of product launches in the uveitis treatment market. For example, in October 2018, EyePoint Pharmaceuticals received FDA approval for Yutiq (fluocinolone acetonide intravitreal implant). This product is used in the treatment of chronic non-infectious uveitis.
- Increasing prevalence of the uveitis across the globe

Market Restraints

- Side-effect related to corticosteroid drugs is likely to hamper the growth of the uveitis treatment market during the forecast period

Uveitis Treatment Market Segmentation

By Type

- **Anterior Uveitis:** In anterior uveitis, inflammation forms in the middle layer of the eye that includes the iris and adjacent tissue. This segment holds the most significant share in the type segment. Mainly topical drops such as corticosteroid drops are prescribed by the physician in the treatment of the anterior uveitis.
- **Intermediate Uveitis:** It occurs in children as well as young adults. It accounts for 2% 31% of all uveitis patients and incidence of the intermediate uveitis between 1.4% to 2% in Germany.
- **Posterior Uveitis:** In posterior uveitis, the inflammation primarily forms in the retina and choroid area of the eye.
- **Others**

By Drug Class

- **Corticosteroids Drugs:** This drug class is most commonly used for the treatment of uveitis. It expected to hold the largest share in the uveitis treatment market due to the increasing preference of this drug class and desirable outcomes. Major corticosteroid brands in the uveitis treatment market are Ozurdex (Allergan PLC) and Triesence suspension (Novartis AG).
- **Anti-Inflammatory Drugs:** In chronic uveitis, non-steroid anti-inflammatory drugs are used to treat inflammation over a more extended period.
- **Immunosuppressive Drugs:** Maximum immunosuppressive agents have significant adverse effects due to which these drugs are not used very often for the treatment of the uveitis.

By End-User

- **Hospitals:** The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals. In 2018, the hospital's segment held the largest share of the uveitis treatment market.
- **Specialty Clinics:** Consisting of long-term care for chronic patients and the elderly, this is a fast-growing market segment, especially in developed nations.
- **Others**

January 2023:Active Biotech reported that their phase I clinical research of an eye drop formulation of laquinimod in healthy participants had been successfully completed. Inflammatory eye illnesses, such as non-infectious uveitis, a sight-threatening eye condition, have an unmet medical need for more therapeutic therapies with a favorable safety and tolerability profile. No safety problems or local toxicity issues were found with the dose regimens examined for the laquinimod eye drop in this trial, which is a promising sign.

August 2023:A local ocular delivery patent for the KIO-100 family of non-steroidal anti-inflammatory small compounds was issued in the United States (Patent No. 11,730,716) and Europe in August 2023, as reported by Kiora Pharmaceuticals, Inc. In addition to protecting Kiora's pipeline, this IP also extends market exclusivity for approved indications in the United States and Europe for a number of inflammatory-related therapeutic applications, such as the treatment of posterior non-infectious uveitis.

Uveitis Treatment Market By Region

- **Americas:**The Americas held the largest regional uveitis treatment market in 2018. The US has over 7,200 active hospitals and a well-established healthcare sector. This serves to drive development in the region's market for uveitis treatment.
- Additionally, increasing the incidence of uveitis in the US is likely to support the growth of the uveitis treatment market. The annual rate of uveitis around 26.6 to 102 per 100,000 adults in the US. Moreover, uveitis has led to about 2.8% of cases of blindness in the US.
- **Europe:** The need for uveitis treatment is high in this region due to the rising prevalence of the uveitis in the region.
- **Asia-Pacific:** The Asia-Pacific is the fastest-growing region for the uveitis treatment market. It has the world's largest population and a fast-developing healthcare sector.
- **Middle East & Africa:** It is projected to account for the least share of the uveitis treatment market due to low per capita disposable incomes in the region and limited development of healthcare facilities.

Uveitis Treatment Market Key Players

- Allergan PLC (Ireland)
- Novartis AG (Switzerland)
- Bausch Health (Canada) EyePoint Pharmaceuticals, Inc. (US)
- AbbVie Inc. (US)
- Horizon Therapeutics Plc (Ireland)
- Mylan NV (US)
- Alimera Sciences (US)
- Others

Table of Content:

Contents
Table of Contents

1. REPORT PROLOGUE	
2. MARKET INTRODUCTION	
2.1. Definition	
2.2. Scope of the Study	
2.2.1. Research Objective	
2.2.2. Assumptions	
2.2.3. Limitations	
3. RESEARCH METHODOLOGY	
3.1. Overview	
3.2. Primary Research	
3.3. Secondary Research	
3.4. Market Size Estimation	
4. MARKET DYNAMICS	
4.1. Overview	
4.2. Drivers	
4.3. Restraints	
4.4. Opportunities	
5. MARKET FACTOR ANALYSIS	
5.1. Porter's Five Forces Analysis	
5.1.1. Bargaining Power of Suppliers	
5.1.2. Bargaining Power of Buyers	
5.1.3. Threat of New Entrants	
5.1.4. Threat of Substitutes	
5.1.5. Intensity of Rivalry	
5.2. Value Chain Analysis/Supply Chain Analysis	
6. GLOBAL UVEITIS TREATMENT MARKET, BY TYPE	
6.1. Overview	
6.2. Anterior Uveitis	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
6.3. Intermediate Uveitis	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
6.4. Posterior Uveitis	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
6.5. Others	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
7. GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS	
7.1. Overview	
7.2. Corticosteroids Drugs	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
7.3. Anti-Inflammatory Drugs	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
7.4. Immunosuppressive Drugs	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
7.5. Others	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
8. GLOBAL UVEITIS TREATMENT MARKET, BY END USER	
8.1. Overview	
8.2. Hospitals	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
8.3. Specialty Clinics	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
8.4. Others	
Market Estimates & Forecast, by Region, 2023-2032	
Market Estimates & Forecast, by Country, 2023-2032	
9. GLOBAL UVEITIS TREATMENT MARKET, BY REGION	
9.1. Overview	
9.2. Americas	
9.2.1. North America	
9.2.1.1. US	

- 9.2.1.2. Canada
- 9.2.2. Latin America
- 9.3. Europe
 - 9.3.1. Western Europe
 - 9.3.1.1. Germany
 - 9.3.1.2. France
 - 9.3.1.3. Italy
 - 9.3.1.4. Spain
 - 9.3.1.5. UK
 - 9.3.1.6. Rest of Western Europe
 - 9.3.2. Eastern Europe
- 9.4. Asia-Pacific
 - 9.4.1. Japan
 - 9.4.2. China
 - 9.4.3. India
 - 9.4.4. Australia
 - 9.4.5. South Korea
 - 9.4.6. Rest of Asia-Pacific
- 9.5. Middle East & Africa
 - 9.5.1. Middle East
 - 9.5.2. Africa
- 10. COMPANY LANDSCAPE
 - 10.1.1. Overview
 - 10.1.2. Competitive Analysis
 - 10.1.3. Market Share Analysis
 - 10.1.4. Major Growth Strategy in the global uveitis treatment market
 - 10.1.5. Competitive Benchmarking
 - 10.1.6. Leading Player in terms of Number of Developments in global uveitis treatment market
 - 10.1.7. Key Developments & Growth Strategies
 - 10.1.7.1. Product Launch
 - 10.1.7.2. Merger & Acquisition
 - 10.1.7.3. Joint Ventures
 - 10.1.8. Major Players Financial Matrix
 - 10.1.8.1. Sales & Operating Income 2023
 - 10.1.8.2. Major Players R&D Expenditure 2023
- 11. COMPANY PROFILES
 - 11.1. Allergan PLC
 - 11.1.1. Company Overview
 - 11.1.2. Product Type Overview
 - 11.1.3. Financial Overview
 - 11.1.4. Key Developments
 - 11.1.5. SWOT Analysis
 - 11.1.6. Key Strategies
 - 11.2. Novartis AG
 - 11.2.1. Company Overview
 - 11.2.2. Product Type Overview
 - 11.2.3. Financial Overview
 - 11.2.4. Key Developments
 - 11.2.5. SWOT Analysis
 - 11.2.6. Key Strategies
 - 11.3. Bausch Health
 - 11.3.1. Company Overview
 - 11.3.2. Product Type Overview
 - 11.3.3. Financial Overview
 - 11.3.4. Key Developments
 - 11.3.5. SWOT Analysis
 - 11.3.6. Key Strategies
 - 11.4. EyePoint Pharmaceuticals, Inc.
 - 11.4.1. Company Overview
 - 11.4.2. Product Type Overview
 - 11.4.3. Financial Overview
 - 11.4.4. Key Developments
 - 11.4.5. SWOT Analysis
 - 11.4.6. Key Strategies
 - 11.5. AbbVie Inc.
 - 11.5.1. Company Overview
 - 11.5.2. Product Type Overview
 - 11.5.3. Financial Overview
 - 11.5.4. Key Developments
 - 11.5.5. SWOT Analysis
 - 11.5.6. Key Strategies
 - 11.6. Horizon Therapeutics PLC
 - 11.6.1. Company Overview
 - 11.6.2. Product Type Overview
 - 11.6.3. Financial Overview
 - 11.6.4. Key Developments
 - 11.6.5. SWOT Analysis
 - 11.6.6. Key Strategies
 - 11.7. Mylan NV
 - 11.7.1. Company Overview
 - 11.7.2. Product Type Overview
 - 11.7.3. Financial Overview
 - 11.7.4. Key Developments
 - 11.7.5. SWOT Analysis
 - 11.7.6. Key Strategies
 - 11.8. Alimera Sciences
 - 11.8.1. Company Overview
 - 11.8.2. Product Type Overview
 - 11.8.3. Financial Overview
 - 11.8.4. Key Developments
 - 11.8.5. SWOT Analysis
 - 11.8.6. Key Strategies
 - 11.9. Others

12. APPENDIX
12.1. References
12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL UVEITIS TREATMENT MARKET SYNOPSIS, 2023-2032
TABLE 2 GLOBAL UVEITIS TREATMENT MARKET ESTIMATES & FORECAST, 2023-2032(USD MILLION)
TABLE 3 GLOBAL UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 4 GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 5 GLOBAL UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 6 GLOBAL UVEITIS TREATMENT MARKET, BY REGION, 2023-2032(USD MILLION)
TABLE 7 NORTH AMERICA: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 8 NORTH AMERICA: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 9 NORTH AMERICA: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 10 US: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 11 US: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 12 US: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 13 CANADA: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 14 CANADA: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 15 CANADA: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 16 LATIN AMERICA: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 17 LATIN AMERICA: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 18 LATIN AMERICA: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 19 EUROPE: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 20 EUROPE: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 21 EUROPE: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 22 WESTERN EUROPE: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 23 WESTERN EUROPE: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 24 WESTERN EUROPE: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 25 EASTERN EUROPE: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 26 EASTERN EUROPE: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 27 EASTERN EUROPE: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 28 ASIA-PACIFIC: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 29 ASIA-PACIFIC: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 30 ASIA-PACIFIC: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: UVEITIS TREATMENT MARKET, BY TYPE, 2023-2032(USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2023-2032(USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: UVEITIS TREATMENT MARKET, BY END USER, 2023-2032(USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL UVEITIS TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL UVEITIS TREATMENT MARKET
FIGURE 4 GLOBAL UVEITIS TREATMENT MARKET SHARE, BY TYPE, 2023 (%)
FIGURE 5 GLOBAL UVEITIS TREATMENT MARKET SHARE, BY DRUG CLASS, 2023 (%)
FIGURE 6 GLOBAL UVEITIS TREATMENT MARKET SHARE, BY END USER, 2023 (%)
FIGURE 7 GLOBAL UVEITIS TREATMENT MARKET SHARE, BY REGION, 2023 (%)
FIGURE 7 AMERICAS: UVEITIS TREATMENT MARKET SHARE BY REGION, 2023 (%)
FIGURE 8 NORTH AMERICA: UVEITIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 9 EUROPE: UVEITIS TREATMENT MARKET SHARE, BY REGION, 2023 (%)
FIGURE 10 WESTERN EUROPE: UVEITIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 11 ASIA-PACIFIC: UVEITIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 12 MIDDLE EAST & AFRICA: UVEITIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 13 GLOBAL UVEITIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 14 ALLERGAN PLC: KEY FINANCIALS
FIGURE 15 ALLERGAN PLC: SEGMENTAL REVENUE
FIGURE 16 ALLERGAN PLC: REGIONAL REVENUE
FIGURE 17 NOVARTIS AG: KEY FINANCIALS
FIGURE 18 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 19 NOVARTIS AG: REGIONAL REVENUE
FIGURE 20 BAUSCH HEALTH: KEY FINANCIALS
FIGURE 21 BAUSCH HEALTH: SEGMENTAL REVENUE
FIGURE 22 BAUSCH HEALTH: REGIONAL REVENUE
FIGURE 23 EYEPOINT PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 24 EYEPOINT PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 25 EYEPOINT PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 26 ABBVIE INC.: KEY FINANCIALS
FIGURE 27 ABBVIE INC.: SEGMENTAL REVENUE
FIGURE 28 ABBVIE INC.: REGIONAL REVENUE
FIGURE 29 HORIZON THERAPEUTICS PLC: KEY FINANCIALS
FIGURE 30 HORIZON THERAPEUTICS PLC: SEGMENTAL REVENUE
FIGURE 31 HORIZON THERAPEUTICS PLC: REGIONAL REVENUE
FIGURE 32 ALIMERA SCIENCES: KEY FINANCIALS
FIGURE 33 ALIMERA SCIENCES: SEGMENTAL REVENUE
FIGURE 34 ALIMERA SCIENCES: REGIONAL REVENUE